Chordate Medical Holding ABs (publ) set-off share issue is now registered

Chordate Medical Holding AB (publ) (“Chordate Medical” or the “Company“) announces that the directed set-off issue to underwriters who have chosen to receive guarantee compensation in the form of newly issued shares in the Company announced on January 18, 2023 (the “Compensation Issue“) has been registered with the Swedish Companies Registration Office (sw. “Bolagsverket”). Distribution of shares is expected to commence on January 25, 2023.

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Compensation Issue.

The information was submitted, through the contact person above, for publication on January 24 at 19.20 2023 (CET).

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy